Stock A334970 PRESTIGE BIOLOGICS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Prestige Biologics Co., Ltd.

Equities

A334970

KR7334970001

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 24/06/2024 am IST 		5-day change 1st Jan Change
4,000 KRW -3.50% Intraday chart for Prestige Biologics Co., Ltd. -3.61% -9.09%
2023 Prestige Biologics Co., Ltd. announced that it has received KRW 45.5 billion in funding from Octava Fund Limited CI
2023 Prestige Biologics Co., Ltd. announced that it expects to receive KRW 45.5 billion in funding from Octava Fund Limited CI

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Prestige Biologics enters into MoU with Aurigene Pharmaceutical Services Limited to explore collaboration in CDMO market
AQ
Prestige Biologics Co., Ltd. announced that it has received KRW 45.5 billion in funding from Octava Fund Limited
CI
Prestige Biologics Co., Ltd. announced that it expects to receive KRW 45.5 billion in funding from Octava Fund Limited
CI
Prestige Biologics Co., Ltd. announced that it has received KRW 6.893915 billion in funding from Prestige BioPharma Limited
CI
Prestige Biologics Co., Ltd. announced that it expects to receive KRW 6.893915 billion in funding from Prestige BioPharma Limited
CI
Prestige BioPharma and Dr. Reddy's Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast Asia
CI
Prestige Biologics Co., Ltd.(KOSDAQ:A334970) added to S&P Global BMI Index
CI
Prestige Biologics Co., Ltd. has completed an IPO in the amount of KRW 91.14 billion.
CI
Prestige Biologics Co., Ltd. has filed an IPO.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A334970 Stock
  4. News Prestige Biologics Co., Ltd.